武警医学2011，Vol.22Issue(10)：879-882,4.
树突状细胞瘤苗联合细胞因子诱导的杀伤细胞治疗非小细胞肺癌的疗效观察
Efficacy of DCTAA combined with CIK in treatment of patients with moderate and ad vanced stage lung cancer
罗社文 1张丹梅 2高锦 2毛积分 1赵风翎 1李哲 1刘明贺 1宋晓萍 1许莉 1王大鹏2
作者信息
- 1. 100039 北京,武警总医院干部病房一科
- 2. 100028 北京京蒙高科干细胞技术有限公司
- 折叠
摘要
Abstract
Objective To observe the efficacy in 48 patients with moderate and advanced lung cancer treated by immuno therapy of the dendritic cells loading of tumor autologous antigen (DCTAA) combined with the cells induced factor of the killer cells (CIK) from the matched umbilical cord blood cells. Methods The peripheral blood mononuclear cells(PBMC) were separated from the matched umbilical cord blood cells, induced to CIK and DC with some cytokines in vitro, such as CD3McAb, IL-2, IFN -^.IL-la, etc . After 12 to 15 days, we obtained the amplified CIK cells and infused the CIK cells back to the patients'body six times under strict quality control, about 5 -8 x 10' CIK cells in each time. On the fifth day of the cultivation, we loaded DC with tumor autologous antigen, obtained DCTAA cells on the eighth day, and then gave a hypodermic injection to lymph nodes. The patient's general condition after the immuno-therapy was observed, such as the size of the tumor, clinical symptom score, the quality of life and immune indexes, Kamofsky score, weight, toxic and side effects, and the patients survival was also studied. Results Of the 48 cases undergoing DCTAA - CIK treatment, complete remission(CR) and partial remission (PR) were effected in 37 cases. The overall remission rate was 77.1%. The improvement rate of clinical symptom scores ranged from 78.9% to 84.7% , and the increase rate of Kamofsky score was 89.6%. One - year survival reached 80.6%. Toxic and side effects were trivial with significant difference (P <0.01). The proportions of CD3 , CD4 and NK cells in peripheral blood cells increased significantly (P <0.01) after DCTAA - CIK cells treatment. Conclusions The DCTAA - CIK immuno therapy is effective for advanced lung cancer by not only improving the immune function but also ameliorating clinical symptoms.关键词
树突状细胞瘤苗/细胞因子诱导的杀伤细胞/肿瘤相关抗原/流式细胞术/中晚期肺癌/过继性细胞免疫治疗Key words
Dendritic cell-based vaccine/ cytokine - induced killer cells/ Tumor associated antigen / flow cytometry/ advanced lung cancer/ Adoptivetumor immunotherapy分类
临床医学引用本文复制引用
罗社文,张丹梅,高锦,毛积分,赵风翎,李哲,刘明贺,宋晓萍,许莉,王大鹏..树突状细胞瘤苗联合细胞因子诱导的杀伤细胞治疗非小细胞肺癌的疗效观察[J].武警医学,2011,22(10):879-882,4.
